Ingo Hartung

Ingo Hartung is a synthetic organic chemist by training with 15 years of experience in the pharmaceutical industry (Schering AG, Bayer AG, Merck Healthcare KGaA). Starting as a medicinal chemistry lab leader working on kinase inhibitors in cancer research as well as on GPCR targets in cardiology research, he moved on to head Bayer's microbiological chemistry group. In 2015 he was promoted to a section head in Bayer's medicinal chemistry department in Berlin/Germany and was responsible for early research activities in epigenetics and subsequently in immuno-oncology. In 2019 he joined Merck Healthcare KGaA in Darmstadt/Germany to lead their MedChem group again covering all areas of SMOL cancer research.